###### Strengths and limitations of this study

-   The strengths of this study include the large sample size, multivariable adjustment and sensitivity analyses to assess the robustness of findings.

-   A limitation of this study is including all patients that were hospitalised in a single regional tertiary centre; these patients were from several different states and some were from other countries. We might have underestimated the mortality or readmission rates if these patients were readmitted to a different hospital closer to their residency place after discharge.

-   A limitation of this study is that the majority of the included patients were white; the results may not be generalisable to people from other races.

Introduction {#s1}
============

Acute decompensated heart failure (ADHF), acute myocardial infarction (AMI) and pneumonia are among the most common causes of hospitalisation in the USA, with more than 2.5 million hospitalisations per year, and estimated annual hospital cost of \$31.3 billion.[@R1] Hospitalised patients with ADHF, AMI or pneumonia are at high risk of death and readmission at 30 days after index hospitalisation.[@R1] In the USA, 15.1% of patients with AMI, 11.4% of patients with ADHF and 11.3% of patients with pneumonia die within 30 days after hospitalisation for respective disorders.[@R3] Likewise, 21.4%, 16% and 16.5% of patients hospitalised for ADHF, AMI and pneumonia, respectively, are readmitted within 30 days of the first hospitalisation.[@R5] Annually, the Centers for Medicare and Medicaid Services publically reports a comprehensive overview of national performance as part of the Hospital Inpatient Quality Reporting Program, using these three conditions.[@R1] Risk standardised 30-day mortality and readmission rates are quality performance measures for AMI, ADHF and pneumonia.[@R6] However, these outcomes vary between men and women.[@R7]

In the past several decades, gender disparities in clinical outcomes of hospitalised patients with different diseases have been investigated.[@R8] Several studies suggested gender differences in clinical outcomes for patients with AMI, ADHF and pneumonia.[@R10]

Women have worse outcomes for pneumonia than men, with adjusted risk ratio of 1.15 for 28-day mortality.[@R14] Women with acute coronary syndromes were at a higher risk for unadjusted in-hospital death (5.6% vs 4.3%)[@R9] and they are more likely to have adverse outcomes (myocardial infarction, stroke and readmission) compared with men (OR 1.24, 95% CI 1.14 to 1.34).[@R15]

Although no gender differences were found in outcomes in patients with ADHF, there were significant gender differences in the clinical characteristics at presentation including age and comorbidities.[@R10]

Multimorbidity, defined as existence of two or more disorders in an individual patient, has become a public health issue of increasing magnitude. Around one-third of all Americans have multimorbidity (31.5%), and the rate is expected to increase with time.[@R16] Multimorbidity is associated with premature death, propensity for overinvestigation, duplicate tests, medication non-adherence, polypharmacy with increased risk for drug adverse events and a decline in functional status.[@R16] Mutlimorbidity itself may have gender disparities. The US National Health and Nutrition Examination Survey when looking at persons 65 years and older found that 83% of women compared with 65% men with coronary artery disease (CAD) had one of the four comorbid conditions (arthritis, chronic lower respiratory tract disease, diabetes mellitus and stroke).[@R17] European data suggest a similar difference in the prevalence of multimorbidity between men and women.[@R18]

Although the above data provide sex-related differences in the prevalence of multimorbidity in specific patient population, the disparity in rates of occurrence of comorbid conditions and their impact on early clinical outcome have not been reported by gender for broader hospitalised patients with ADHF, AMI and pneumonia.

To address this gap in knowledge, we evaluated gender-specific differences in the prevalence of individual and multiple comorbid conditions in a large hospital-based patient population with ADHF, AMI and pneumonia. Furthermore, we determined whether the presence of individual or multimorbidity impacts 30-day mortality or readmission by gender independent of demographic and social characteristics.

Methods {#s2}
=======

Study design and population sample {#s2a}
----------------------------------

This is a retrospective study of patients aged ≥18 years hospitalised for ADHF, AMI and pneumonia at Mayo Clinic, Rochester, Minnesota, from 1 January 1995 to 31 August 2015.

We included first hospitalisation in the analysis when a patient had multiple repeat hospitalisations for the same condition, since patients with multiple hospitalisations with the same condition may have higher risk of readmission or mortality within 30 days. The data were extracted by dedicated abstraction personnel using International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes (online [supplementary tables 1--3](#SP1){ref-type="supplementary-material"}). We abstracted data related to age, gender, race, zip code, insurance, principal discharge diagnosis, secondary diagnoses, length of hospital stay, death and readmission by date. The diagnoses of AMI, ADHF and pneumonia were based on physician provider as documented in clinical notes. Patients who refused participation in clinical research were excluded.
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Patient and public involvement {#s2b}
------------------------------

Patients and public were not involved.

Measure of multicomorbidities {#s2c}
-----------------------------

Comorbidities were chosen from 20 chronic conditions (online [supplementary tables 4](#SP1){ref-type="supplementary-material"}) specified by the Office of the Assistant Secretary for Health[@R19] using ICD-9-CM codes (online [supplementary tables 5](#SP1){ref-type="supplementary-material"}). Multicomorbidities were categorised into four groups based on the number of existing chronic conditions: less than two comorbidities, two comorbidities, three comorbidities and four or more comorbidities.

We did not use composite morbidity index such as Charlson, since it needed to be modified for this study. For example, we did not count CAD as one of the comorbidities for patients hospitalised for AMI, the same for congestive heart failure for patients with ADHF.

We excluded four comorbid conditions (autism, schizophrenia, hepatitis and HIV) from the analysis because of very low frequency of occurrence (\<1%).

Measures of outcomes {#s2d}
--------------------

The primary outcomes were prevalence of comorbidities in men and women, 30-day mortality, defined as 30 days from the day of admission with one of the primary diagnosis, and 30-day readmission for any cause since discharge date.

Statistical analysis {#s2e}
--------------------

Baseline characteristic data were summarised as mean and SD for continuous variables and as for categorical variables. Prevalence of comorbidities and the number of multimorbidities in men and women were compared using χ^2^ tests.

Gender differences in 30-day mortality and 30-day readmission were presented as OR. Logistic regression models were developed to estimate the risk of outcomes of interest while controlling for various confounders (age, length of stay, Olmsted county residency and number of comorbidities). Results are reported as ORs and 95% CIs. A two-tailed p value \<0.05 was considered as statistically significant and all analyses were performed using STATA V.14.0 (StataCorp, College Station, Texas, USA).

Results {#s3}
=======

A total of 40 971 patients were included during the study period: 12 265 with ADHF, 15 777 with AMI and 12 929 with pneumonia. There were more men in all three conditions, and men were younger ([table 1](#T1){ref-type="table"}).

###### 

Baseline characteristics

                   AMI=15 777    ADHF = 12 265   Pneumonia=12 929                                                                      
  ---------------- ------------- --------------- ------------------ -------------- ------------- --------- ------------- ------------- ---------
  Age (SD)         66.5 (13.3)   73 (13.3)       \<0.001            72.3 (13)      75.4 (13.9)   \<0.001   69.2 (16.8)   70.8 (17.7)   \<0.001
  Race **%**                                                                                                                           
   Non-white       12.74%        14.12%          0.015              14.25 %        14.25%        0.997     15.65%        14.70%        0.14
   White           87.26%        85.88%          85.75 %            85.75%         84.35%        85.30%                                
  Comorbidity                                                                                                                          
   Arthritis       3.37%         5.57%           0.06               4.35%          6.95%         \<0.001   4.28%         7.26%         \<0.001
   Asthma          2.42%         3.89%           \<0.001            2.81%          5.25%         \<0.001   5.09%         10.31%        \<0.001
   Dementia        1.73%         3.29%           \<0.001            2.65%          4.17%         \<0.001   6.9%          8.52%         0.001
   Depression      4.4%          6.8%            \<0.001            6.28%          9.12%         \<0.001   8.64%         12.93%        \<0.001
   Hypertension    57.64%        65.69%          \<0.001            56.52%         62.11%        \<0.001   43.91%        48.80%        \<0.001
   Osteoporosis    0.4%          4.73%           \<0.001            0.97%          7.16%         \<0.001   2.09%         9.00%         \<0.001
   Cancer          8.14%         6.95%           0.01               13.42%         11.91%        0.01      25.93%        17.81%        \<0.001
   Drug abuse      4.15%         1.47%           \<0.001            3.65%          0.97%         \<0.001   4.54%         2.36%         \<0.001
   Dyslipidaemia   44.46%        40.40%          \<0.001            1.06%          27.73%        \<0.001   20.54%        17.71%        \<0.001
  CAD                                                               56.98%         41.27%        \<0.001   27.29%        17.78%        \<0.001
   CHF             21.15%        29.03%          \<0.001                                                   20.44%        21.36%        0.20
   CKD             9.49%         9.24%           0.60               27.93%         21.62%        \<0.001   15.28%        10.71%        \<0.001
   COPD            11.02%        10.84%          0.73               23.50%         16.67%        \<0.001   28.19%        22.8%         \<0.001
   Diabetes        26.18%        29.62%          \<0.001            33.75%         32.31%        0.09      22.78%        19.31%        \<0.001
   Arrhythmia      25.62%        27.03%          0.06               60.93%         54.23%        \<0.001   28.36%        24.80%        \<0.001
   Stroke          3.35%         4.49%           \<0.001            2.84%          2.42%         0.15      2.52%         1.67%         0.001
  Length of stay                                                                                                                       
   Mean (SD)       5.42 (5.83)   5.67 (5.76)     0.01               6.02 (10.22)   5.71 (8.33)   0.07      5.36 (6.01)   5.13 (6.41)   0.04

ADHF, acute decompensated heart failure; AMI, acute myocardial infarction; CAD, coronary artery disease; CHF, congestive heart failure; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease.

The prevalence of each comorbidity in men and women was reported in [table 1](#T1){ref-type="table"}. The majority of deaths due to AMI occurred in the first 10 days, whereas this trend was not evidence for pneumonia or ADHF (online [supplementary figure 1--3](#SP1){ref-type="supplementary-material"}). The majority of readmissions for all three conditions occurred in the first 15 days (online [supplementary figure 4--6](#SP1){ref-type="supplementary-material"}).

Summary of outcomes {#s3a}
-------------------

### ADHF {#s3a1}

A total of 12 265 patients were hospitalised with ADHF within the study period: 7010 men and 5255 women. Women were older with a mean age of 75.4 years compared with 72.3 years in men. 85.75% of both men and women were Caucasian. 71.94% of men had multicomorbidities compared with 69.99% of women.

After adjusting for age, length of stay, residence place (Olmsted county vs non-Olmsted) and multicomorbidities, OR for 30-day mortality for men versus women was 0.94 (95% CI 0.82 to 1.07), and OR for 30-day readmission was 0.90 (95% CI 0.82 to 0.99) ([table 2](#T2){ref-type="table"} and [figure 1](#F1){ref-type="fig"}).

![Adjusted outcomes 30-day mortality and 30-day readmission in men versus women. ADHF, acute decompensated heart failure; AMI, acute myocardial infarction.](bmjopen-2018-022782f01){#F1}

###### 

Adjusted outcomes

  Men versus women     AMI                         ADHF   Pneumonia                                                
  -------------------- --------------------------- ------ ------------------------ ------ ------------------------ -------
  30-day mortality     OR 0.98 (0.86 to to 1.11)   0.71   OR 0.94 (0.82 to 1.07)   0.39   OR 1.19 (1.06 to 1.34)   0.004
  30-day readmission   OR 0.90 (0.79 to 1.04)      0.16   OR 0.90 (0.82 to 0.99)   0.03   OR 1.10 (0.99 to 1.23)   0.08

ADHF, acute decompensated heart failure; AMI, acute myocardial infarction.

A subgroup analysis including patients who had CAD was conducted, OR for 30-day mortality was 0.89 (95% CI 0.73 to 1.09), and OR for 30-day readmission was 0.90 (95% CI 0.75 to 1.082).

### AMI {#s3a2}

Of the 15 777 patients hospitalised with AMI, 10 280 were men and 5497 were women. Women were older, with a mean age of 73 years compared with 66.5 years in men. 86.78% of patients were Caucasian (87% of men and 86% in women) ([table 1](#T1){ref-type="table"}). 46.73% of men had multicomorbidities compared with 52.17% of women.

After adjusting for age, length of stay, residence place (Olmsted county vs non-Olmsted) and multicomorbidities, OR for 30-day mortality for men versus women was 0.98 (95% CI 0.86 to 1.11), and OR for 30-day readmission was 0.90 (95% CI 0.79 to 1.04) ([table 2](#T2){ref-type="table"} and [figure 1](#F1){ref-type="fig"}).

A subgroup analysis including patients who had heart failure was conducted, OR for 30-day mortality was 1.18 (95% CI 1.007 to 1.37) and OR for 30-day readmission was 0.89 (95% CI 0.72 to 1.09).

Pneumonia {#s3b}
---------

Of the 12 929 patients hospitalised with pneumonia within the study period, three were 7073 men and 5856 women. Women were older with a mean age of 70.8 compared with 69.2 years in men. 85% of both men and women were Caucasian. 58.89% of men had multicomorbidities compared with 55.79% of women.

After adjusting for age, length of stay, residence place (Olmsted county vs non-Olmsted) and multicomorbidities, OR for 30-day mortality for men versus women was 1.19 (95% CI 1.06 to 1.34), and OR for 30-day readmission was 1.10 (95% CI 0.99 to 1.23). ([table 2](#T2){ref-type="table"}) ([figure 1](#F1){ref-type="fig"})

A subgroup analysis including patients who had CAD was conducted, OR for 30-day mortality was 1.21 (95% CI 0.93 to 1.56) and OR for 30-day readmission was 1.06 (95% CI 0.81 to 1.39).

A subgroup analysis including patients who had heart failure was conducted, OR for 30-day mortality was 1.089 (95% CI 0.89 to 1.33) and OR for 30-day readmission was 1.21 (95% CI 1.007 to 1.46).

Sensitivity analysis {#s3c}
--------------------

To determine the contemporary status of gender disparities and comorbidities, we conducted a sensitivity analysis focusing on patients who were admitted in the last 5 years. The results were overall consistent with the main analysis, except for 30-day mortality for pneumonia (which became non-significant between men and women whereas mortality was marginally higher in men, in the original analysis) (online [supplementary table 6](#SP1){ref-type="supplementary-material"}).

We conducted another sensitivity analysis, looking for 15-day mortality and readmission. There were no statistically significant differences in 15-day readmission between men and women in all three conditions. 15-day mortality was marginally higher for pneumonia in men for OR 1.15 (95% CI 1.00 to 1.33) but not statistically significant different in AMI or ADHF (online [supplementary table 7](#SP1){ref-type="supplementary-material"}).

Discussion {#s4}
==========

This study suggests that comorbidities are distributed differently between men and women hospitalised for ADHF, AMI and pneumonia. Despite a fairly large sample size, this study showed that gender differences appear to have minimal meaningful impact on outcomes.

In AMI, women are known to less commonly report chest pain or discomfort compared with men; this may lead to gender differences in outcomes of AMI.[@R20] However, in our study, the gender difference in 30-day mortality could be explained by the age difference: women were 6.5 years older on average. After adjusting for residency location and number of comorbidities, age had a significant impact on 30-day mortality, but not gender or multicomorbidities. On the other hand, the only factor that had a significant association with 30-day readmission was multicomorbidities.

In ADHF, men had significantly lower 30-day readmission rate compared with women, while they did not have a significant difference in 30-day mortality. A sensitivity analysis including only patients for the last 5 years showed similar results. Multicomorbidity did not have a significant effect on 30-day mortality or readmission. This might be explained by difference in symptoms presentations or difference in access to medical care between men and women. For example, men used to have higher invasive cardiac procedures than women in a previously published study.[@R21]

Men with pneumonia had significantly higher 30-day mortality compared with women, but no significant difference in 30-day readmission. Multicomorbidities had a significant effect on 30-day readmission in men but not in women.

Comparison with existing literature {#s4a}
-----------------------------------

Our findings in AMI were consistent with previously published studies[@R12] that showed a higher 30-day mortality rate in women verses men, but no significant difference after adjustment for other variables. In these studies, they include elderly patients only (\>65 years old) while we had no age restriction, but yet, in all of these studies, women were older, and had differences in comorbidities compared with men. In ADHF, our results were consistent with a previously published study that used Acute Decompensated Heart Failure National Registry between 2001 and 2004[@R10]; in both studies, there was no significant difference in in-hospital mortality between men and women.

In pneumonia, our study showed that men have worse outcomes than women, unlike a previous study[@R14] that found that women have worse outcomes for community-acquired pneumonia with 28-day mortality OR of 1.15 (95% CI 1.02 to 1.30). However, our study included all types of pneumonia, and it was consistent with another study that used the Medicare database and showed worse outcomes in men.[@R23]

Limitations and strengths {#s4b}
-------------------------

A limitation of this study is that we used ICD-9 codes for identifying patients. It was not feasible to review charts for such a large number of patients; therefore, we had to depend on administrative and billing codes. New research using the recent ICD-10 coding is needed to study the consistency of prevalence and implication of comorbidities on early outcomes in hospitalised patients. Another limitation is that we included all patients that were hospitalised in a single regional tertiary centre; these patients were from several different states and some were from other countries. We might have underestimated the mortality or readmission rates if these patients were readmitted to a different hospital closer to their residency place after discharge. Making this less concerning is the fact that we found gender to be an independent variable from residency place; in addition, we adjusted for residency place (Olmsted county where the hospital is vs non-Olmsted county). Another limitation is that the majority of our included patients were white; our results may not be generalisable to people from other races. Other limitation in our data is that we have included only the first hospitalisation; some patients have likely had multiple repeat hospitalisations for the same condition. The strengths of this study include the large sample size, multivariable adjustment and sensitivity analyses to assess robustness of findings.

Clinical and policy implication {#s4c}
-------------------------------

Although this study showed that women hospitalised for ADHF had higher 30-day readmission rate, the absolute risk was small with a number needed to harm 88 patients (95% CI 48 to 445). For pneumonia, women had lower mortality, with a number needed to harm 61 patients (95% CI 36 to 202). With this minimal clinically meaningful impact of these differences on the early outcomes of these three important conditions, efforts to address gender difference may need to be diverted towards targeting overall population health, where outcomes of these conditions are still suboptimal in both genders, or towards reducing race/ethnicity disparity, or improving access to care differences.

Conclusion {#s5}
==========

Gender disparities interact with comorbidities and impact mortality and readmission. However, this effect varies according to the conditions, seems to be unpredictable and has a minimal meaningful impact on outcomes.
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